IFN beta biobetter (HanAll Biopharma)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameIFN beta biobetter (HanAll Biopharma)
Drug Alias NameHL-144
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionInterferon beta modulators
TargetsInterferon beta
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHanAll Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHanAll Biopharma Co Ltd
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A